Aravive, Inc(NASDAQ:ARAV) 
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ...
Website: http://www.aravive.com
Founded: 2008
Full Time Employees: 16
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-12-19
P
O 0.13
H 0.13
L 0.13
C 0.13
V 632,219
10EMA 0.13
20EMA 0.13
60EMA 0.13
120EMA 0.13
250EMA 0.13